An estimated 1 735 350 new cases of cancer were diagnosed in the United States in 2018, and the population of long-term cancer survivors continues to increase ([@pkz098-B1]). Approximately 15.5 million people in the United States in the year 2016 were classified as cancer survivors ([@pkz098-B2]), defined by the National Cancer Institute as "one who remains alive and continues to function during and after overcoming a serious hardship or life-threatening disease. In cancer, a person is considered to be a survivor from the time of diagnosis until the end of life" ([@pkz098-B1]). This is approximately 5% of the American population; the number of cancer survivors is expected to increase to 26.1 million by the year 2040 ([@pkz098-B2]). As the prevalence of cancer survivors continues to increase and their survival time lengthens, clinicians and researchers have recognized the importance of addressing the side effects of treatment burden to improve quality of life.

The experience of a cancer diagnosis and its resulting treatments are associated with a wide range of physical and psychosocial changes such as fatigue, functional limitations, pain, cognitive changes, and psychological problems ([@pkz098-B3]). Cancer-related fatigue (CRF) is a perceived state of reduction in mental and physical performance that is one of the most commonly reported symptoms accompanying cancer diagnosis and treatment ([@pkz098-B4]). Approximately 40% of patients with malignant disease experience CRF at the time of diagnosis, and up to 90% of patients undergoing radiation or chemotherapy treatment experience CRF ([@pkz098-B5]). For one-third of cancer survivors, fatigue persists after the conclusion of treatment for years ([@pkz098-B7]); in breast cancer survivors, 34% report fatigue 5--10 years after treatment completion ([@pkz098-B8]).

Many factors are thought to contribute to the development of CRF, including the direct effects of the disease, subsequent effects of cancer treatment, psychosocial factors, and comorbid physical symptoms ([@pkz098-B9]). Psychosocial factors are strongly associated with CRF, particularly depressive symptoms ([@pkz098-B10]), which may increase the risk for treatment-associated CRF, although the relationship between depression and CRF is more likely to be bi-directional ([@pkz098-B8]). Recent evidence also suggests a relationship between inflammation and CRF, particularly long-term changes in the levels of circulating markers of proinflammatory cytokine activity ([@pkz098-B11]). CRF is associated with elevated serum levels of proinflammatory cytokines that may persist up to 5 years after diagnosis. Increased CRF has also been associated with lower quality of life in several domains as well as increases in comorbid physical symptoms, such as sleep disturbance and pain ([@pkz098-B4]).

In recent years, mind-body interventions are increasingly used by cancer survivors to aid in coping with these treatment-related symptoms, with yoga used most frequently ([@pkz098-B12]). Originating in ancient Indian philosophy based in mindfulness and spiritual practice, yoga in Western society is most often practiced by performing physical exercises (asana), breathing exercises (pranayama), and meditation (dhyana) ([@pkz098-B13]). Yoga is increasingly recommended as a holistic wellness approach in Western society ([@pkz098-B14]). The National Center for Complementary and Integrative Health reports that current recommendations include yoga to treat specific medical conditions, such as cancer, and to maintain health and well-being ([@pkz098-B15]). A range of yoga-based interventions for cancer survivors has been designed to reduce symptoms that are related to cancer or its treatment and impair quality of life, particularly fatigue. Different types of yoga have different modalities and foci, and require different levels of physical exertion.

Although, in general, studies show support for the effects of yoga-based interventions in reducing fatigue ([@pkz098-B16],[@pkz098-B17]), some do not show a statistically significant benefit over treatment as usual ([@pkz098-B18]). In addition, primary studies alone do not allow for analysis of the efficacy of specific components of the intervention design, such as length of the intervention, type of yoga practiced, and timing of the intervention regarding treatment. It may be that yoga-based interventions are effective in treating fatigue overall but that an intervention that is too long or begun too close to primary treatment may place additional burden on cancer survivors, negatively affecting treatment-related symptoms. A more comprehensive analysis of both intervention and clinical characteristics across cancer types can inform further development of yoga-based interventions in cancer populations.

Previous systematic reviews and meta-analyses have addressed the efficacy of yoga interventions primarily among Caucasian female breast cancer patients ([@pkz098-B19]), who face a much better prognosis than patients with many other cancer types ([@pkz098-B23]). Due to systematic variation across cancer types in recurrence, mortality rates, and treatment burden ([@pkz098-B24]), uncertainty exists regarding the efficacy of yoga interventions in cancer types with higher rates of recurrence and mortality, such as ovarian or lung cancer. To our knowledge, only one other published meta-analysis has included nonbreast cancer survivors in their study search criteria ([@pkz098-B25]). Although methodologically rigorous, that meta-analysis included 10 studies, with only four reporting fatigue outcomes. The current review comprehensively examines the evidence of yoga interventions associated with changes in fatigue, depressive symptoms, and quality of life across cancer types and explores specific patient and intervention characteristics that may be potential moderators of intervention effects. The current meta-analysis was intended to further build on the findings of prior systematic reviews by examining intervention-related and patient-related characteristics that may moderate the consistency of yoga-related effects. We conducted a comprehensive meta-analysis of randomized controlled trials examining the effects of yoga-based interventions on fatigue, depression, and quality of life across cancer populations. The specific aims were to 1) review the evidence of yoga interventions in treating fatigue, depressive symptoms, and poor quality of life in cancer survivors; 2) examine the efficacy of interventions for improving patient-reported outcomes, including fatigue, depression, and quality of life; and 3) identify components of efficacious interventions.

Methods
=======

Inclusion/Exclusion Criteria
----------------------------

This study followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines for systematic reviews. We included all randomized controlled trials of yoga-based interventions that examined effects on fatigue in adult patients diagnosed with any type of cancer in the current systematic review and meta-analysis. To capture the full range of cancer survivorship, the broadest definition of cancer survivor was deployed, allowing inclusion of individuals diagnosed with cancer of any stage and at any time in the treatment trajectory.

To qualify, interventions had to include either group-based or home-based yoga as the core component of the intervention. Studies were excluded for the following reasons: ([@pkz098-B1]) not a published, peer-reviewed article, ([@pkz098-B2]) not written in English, ([@pkz098-B3]) data unavailable to compute standardized effect sizes, ([@pkz098-B4]) no fatigue outcomes reported, ([@pkz098-B5]) data already present in another included study, ([@pkz098-B6]) no comparison group included (defined as no control group within the same population), ([@pkz098-B7]) participants not limited to solely cancer survivors, ([@pkz098-B8]) study quality score (as described below) less than 5.

Information Sources and Search Strategy
---------------------------------------

We searched two databases, PubMed and PsycInfo, from their inception until October 2018 without language restrictions for combinations of search terms related to yoga, cancer, and the relevant cancer survivorship outcomes (ie, fatigue). Citations from recent meta-analyses and systematic reviews were also reviewed.

Data Abstraction
----------------

All abstracts and articles identified during the literature search were coded independently by two different raters (J.S.A. and G.M.). Duplicate citations were first removed. Citations and abstracts were then screened by the authors for fulfillment of eligibility criteria. Any study that did not meet one or more criteria was excluded and assigned a reason for exclusion. The remaining full-text articles were then reviewed to assess eligibility. Standardized data entry spreadsheets were developed by the first author for coding both study-level and effect size data. The additional rater was trained by the first author through coding an initial sample of studies (n = 5), which was then compared for reliability. Inter-rater reliabilities were in the strong range (K = 0.84) ([@pkz098-B26]). When sufficient data for computing standardized effect sizes were unavailable, study authors were contacted via email for additional data.

The following data were extracted: 1) bibliographic information (ie, author, year of publication, journal type); 2) study information (ie, primary and secondary outcomes, type of control group, follow-up timepoint(s), retention); 3) intervention information (ie, yoga type, duration and dose of intervention, setting and format of delivery); 4) participant characteristics (ie, age, sex, race, cancer type and stage, current treatment); 5) outcomes (ie, outcome measures used, hypothesized and observed findings); and 6) data required for effect size calculations.

Study Quality and Bias
----------------------

A study quality score (0--10) was developed based on the Consolidated Standards of Reporting Trials statement for randomized controlled trials ([@pkz098-B27],[@pkz098-B28]). One point was awarded for each criterion, including: 1) full description of randomization and concealment process; 2) baseline demographic and clinical characteristics reported separately for each study group; 3) acceptable participant attrition rate (≤20% for ≤6 months postbaseline; ≤30% for \>6 months postbaseline); 4) assessor blinding; 5) defined and prespecified primary and secondary outcomes identified and measured with validated measures; 6) intention-to-treat analyses and appropriate approach to missing data; 7) potential confounders, including baseline levels of fatigue accounted for in analyses; 8) power calculation reported and trial adequately powered for the primary outcome; 9) use of validated behavioral measurements tools; and 10) summary results presented with between-group difference and precision estimates.

We also assessed publication bias by visually inspecting funnel plots for asymmetry within the model of interest then reestimating models using trim-and-fill methods accounting for asymmetric distribution of studies around an omnibus effect ([@pkz098-B29]).

Statistical Analysis
--------------------

Changes from preintervention assessment to postintervention assessment were obtained directly from the reported study results or calculated by determining the difference between the reported means before and after the intervention (using the first follow-up time-point after the end of the intervention). Study outcomes were analyzed using standardized mean differences (Hedges' g) between outcomes for cancer patients receiving a yoga intervention ("yoga practice") compared with cancer patients who did not, because this method helps reduce positive bias in small samples ([@pkz098-B30]). A positive standardized mean difference indicates positive effects of the yoga intervention in reducing fatigue or depression when compared with the control group. For the purposes of our analyses, all effect sizes for studies where lower scores represent lower fatigue or depression were multiplied by −1 to reverse-code fatigue and depression scores and ensure a similarly coded metric across all included studies. For one study where the SDs were not available, a Cohen's d was calculated using the *t* value of the difference between groups in fatigue ([@pkz098-B31]) and then converted to a Hedges' g using the J conversion value ([@pkz098-B30]).

Analyses were conducted using the R statistical software (version 3.5.0) and the 'metafor' package (version 2.0--0) ([@pkz098-B29]). The 95% confidence intervals are reported. Random effects models were used, assuming statistical heterogeneity between studies. Heterogeneity was explored by Cochrane's Q test and I^2^, which may be interpreted as the proportion of the total between-study variation observed that is attributable to extant differences between studies rather than sampling error. A mixed-effects model was used to assess relevant moderators, including frequency of intervention, length of yoga session, and length of overall intervention. Studies without clear defining characteristics for a moderator (eg, studies that did not specify whether mindfulness was an intervention component) were excluded from that moderation analysis. In addition to the assessments of model heterogeneity described above, the R^2^ index is reported to describe the heterogeneity accounted for by each moderator. A *P* value of less than .05 was considered statistically significant and all tests were two-sided.

Results
=======

Study Selection
---------------

A total 156 citations were retrieved. After application of exclusion criteria, 29 studies met the inclusion criteria involving a total of 1828 participants (see [Figure 1](#pkz098-F1){ref-type="fig"} for PRISMA flow diagram). Included studies were published between 2007 and 2018.

![PRISMA flow diagram of reviewed articles. RCT = randomized controlled trial.](pkz098f1){#pkz098-F1}

Study and Participant Characteristics
-------------------------------------

The average age of participants was 55 years and 57% had some postsecondary education. Female breast cancer survivors accounted for 72% of the sample. The largest number of trials ([@pkz098-B17]) was conducted in the United States (59%). Seven studies were conducted in Asia, four in Europe, and one in Australia. The largest proportion of studies used a waitlist comparison condition (41%). The average follow-up time posttreatment was 2.3 months (SD = 0.98, range = 1.5--6 months).

The median sample size was 62 randomly assigned participants per study (range = 15--200). A total 48% of studies included patients currently in primary cancer treatment. Twenty-four studies targeted only breast cancer survivors, two colorectal cancer, and one prostate cancer. The remaining two studies included multiple cancer types. All studies conducted in the United States reported race or ethnicity demographics, and the majority of the participants in these trials were made up of predominately Caucasian participants. However, two studies specifically targeted minority women ([@pkz098-B18],[@pkz098-B32]). Six studies targeted early-stage cancer survivors, one late-stage cancer survivors, and the remaining 22 studies did not place restrictions on cancer stage at diagnosis. Overall, the majority of participants in these trials were middle-aged, Caucasian, identified as female, and were diagnosed with breast cancer. Twenty-one of the included studies have not been previously included in any published systematic review, with five of these newly included studies published within the last 2 years.

The average duration of the intervention was 2.3 months (SD = 0.95, range = 1--6 months). The average length of each yoga session was 77 minutes (SD = 24, range = 15--120 minutes), and the average number of sessions was 19.8 (SD = 20.2, range = 6--120). The intervention with the fewest sessions was a pranayama intervention consisting of four breathing techniques taught in six weekly classes. Eight studies identified as randomized controlled pilot or feasibility studies. Twelve studies used a waitlist control group, seven studies used a "treatment as usual" or standard care group, and 10 studies used an "active" control (supportive counseling, stretching, or exercise course). Seventeen studies incorporated mindfulness-based theory into the intervention material. A summary of the participant and intervention characteristics of each trial is provided in [Table 1](#pkz098-T1){ref-type="table"}.

###### 

Summary of yoga trial study and participant characteristics[\*](#tblfn1){ref-type="table-fn"}

  First author                                                 Participants                                                          Intervention                                                                                                                                                                                          Design and outcomes
  ------------------------------------------------------------ --------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------
  Banasik et al. (2009) ([@pkz098-B16])Country: USA            n = 18Age: 62.9 yType: breastStage: mixedIn treatment: not reported   Yoga type: IyengarMindfulness-based: noInterventionist(s): yoga instructorDuration & frequency: 2 mo, \>1×/wkSession length: 90 min                                                                   Comparison group: waitlistFollow-up: 2 moOutcomes: fatigue, QoL
  Ben-Josef et al. (2017) ([@pkz098-B33])Country: USA          n = 50Age: 67.3 yType: prostateStage: earlyIn treatment: yes          Yoga type: EischensMindfulness-based: noInterventionist(s): yoga instructorDuration & Frequency: 2 mo, \>1×/wkSession length: 75 min                                                                  Comparison group: usual careFollow-up: 2 moOutcomes: fatigue
  Bower et al. (2012) ([@pkz098-B34])Country: USA              n = 31Age: 53.9 yType: breastStage: earlyIn treatment: no             Yoga type: IyengarMindfulness-based: noInterventionist(s): yoga instructorDuration & frequency: 3 mo, \>1×/wkSession length: 90 min                                                                   Comparison group: health educationFollow-up: 3 moOutcomes: fatigue, depression
  Carson et al. (2009) ([@pkz098-B35])Country: USA             n = 37Age: 54.4 yType: breastStage: earlyIn treatment: no             Yoga Type: gentle yoga poses, meditation,and breathing exercisesMindfulness-based: yesInterventionist(s): yoga instructor and psychologistDuration & frequency: 2 mo, weeklySession length: 120 min   Comparison group: waitlistFollow-up: 2 moOutcomes: fatigue, depression
  Chakrabarty et al. (2015) ([@pkz098-B36])Country: India      n = 160Age: 43.6 yType: breastStage: mixedIn treatment: yes           Yoga type: PranayamaMindfulness-based: noInterventionist(s): not reportedDuration & frequency: 1.5 mo, \>1×/wkSession length: 18 min (approximate)                                                    Comparison group: usual careFollow-up: 1.5 moOutcomes: fatigue
  Chandwani et al. (2014) ([@pkz098-B37])Country: USA          n = 109Age: 51.8 yType: breastStage: mixedIn treatment: yes           Yoga type: PranayamaMindfulness-based: yesInterventionist(s): yoga instructorDuration & frequency: 1.5 mo, \>1×/wkSession length: 60 min                                                              Comparison group: stretching exercisesFollow-up: 1.5 moOutcomes: fatigue, QoL, depression
  Chaoul et al. (2018) ([@pkz098-B38])Country: USA             n= 142Age: 50.0 yType: breastStage: mixedIn Treatment: Yes            Yoga type: TibetanMindfulness-based: yesInterventionist(s): yoga instructorDuration & frequency: 1 mo, weeklySession Length: 83 minutes (approximate)                                                 Comparison group: stretching exercisesFollow-up: 1 moOutcomes: fatigue
  Cramer et al. (2015) ([@pkz098-B39])Country: Germany         n = 40Age: 49.2 yType: breastStage: mixedIn treatment: no             Yoga type: HathaMindfulness-based: yesInterventionist(s): yoga instructorDuration & frequency: 3 mo, weeklySession length: 90 min                                                                     Comparison group: usual careFollow-up: 3 moOutcomes: fatigue, QoL, depression
  Cramer et al. (2016) ([@pkz098-B40])Country: Germany         n = 54Age: 68.3 yType: colorectalStage: mixedIn treatment: yes        Yoga type: HathaMindfulness-based: yesInterventionist(s): yoga instructorDuration & frequency: 2.5 mo, weeklySession length: 90 min                                                                   Comparison group: waitlistFollow-up: 2.5 moOutcomes: fatigue, QoL, depression
  Danhauer et al. (2009) ([@pkz098-B41])Country: USA           n = 44Age: 55.8 yType: breastStage: mixedIn treatment: yes            Yoga type: restorativeMindfulness-based: not reportedInterventionist(s): yoga instructorDuration & frequency: 2.5 mo, weeklySession length: 75 min                                                    Comparison group: waitlistFollow-up: 2.5 moOutcomes: fatigue, QoL, depression
  Dhruva et al. (2012) ([@pkz098-B42])Country: USA             n = 16Age: 54.2 yType: mixedStage: mixedIn treatment: yes             Yoga type: PranayamaMindfulness-based: not reportedInterventionist(s): yoga instructorDuration & frequency: 1.5 mo, weeklySession length: 60 min                                                      Comparison group: waitlistFollow-up: 1.5 moOutcomes: fatigue, QoL, depression
  Johns et al. (2015) ([@pkz098-B43])Country: USA              n = 35Age: 57.3 yType: mixedStage: mixedIn treatment: yes             Yoga type: HathaMindfulness-based: yesInterventionist(s): psychologistDuration & frequency: 1.75 mo, weeklySession length: 120 min                                                                    Comparison group: waitlistFollow-up: 1.75 moOutcomes: fatigue, depression
  Jong et al. (2018) ([@pkz098-B44])Country: The Netherlands   n = 83Age: 51.0 yType: breastStage: mixedIn treatment: yes            Yoga type: DruMindfulness-based: noInterventionist(s): yoga instructorDuration & frequency: 3 mo, weeklySession length: 75 min                                                                        Comparison group: waitlistFollow-up: 3 moOutcomes: fatigue, depression
  Kiecolt-Glaser et al. (2014) ([@pkz098-B17])Country: USA     n = 200Age: 51.6 yType: breastStage: mixedIn treatment: no            Yoga type: HathaMindfulness-based: noInterventionist(s): yoga instructorDuration & frequency: 3 mo, \>1×/wkSession length: 90 min                                                                     Comparison group: waitlistFollow-up: 3 moOutcomes: fatigue, depression
  Littman et al. (2012) ([@pkz098-B45])Country: USA            n = 63Age: 59.4 yType: breastStage: mixedIn treatment: no             Yoga type: HathaMindfulness-based: not reportedInterventionist(s): not reportedDuration & frequency: 6 mo, \>1x/wkSession length: 75 min                                                              Comparison group: waitlistFollow-up: 6 moOutcomes: fatigue, QoL
  Lötzke et al. (2016) ([@pkz098-B46])Country: Germany         n = 92Age: 51.2 yType: breastStage: mixedIn treatment: yes            Yoga type: IyengarMindfulness-based: noInterventionist(s): yoga instructorDuration & frequency: 3 mo, weeklySession length: 60 min                                                                    Comparison group: exercise classFollow-up: 3 moOutcomes: fatigue, QoL
  Loudon et al. (2014) ([@pkz098-B47])Country: Australia       n = 28Age: 57.8 yType: breastStage: mixedIn treatment: no             Yoga type: SatyanandaMindfulness-based: not reportedInterventionist(s): yoga instructorDuration & frequency: 2 mo, \>1×/wkSession length: 90 min                                                      Comparison group: waitlistFollow-up: 2 moOutcomes: fatigue, QoL
  Moadel et al. (2007) ([@pkz098-B18])Country: USA             n = 128Age: 54.8 yType: breastStage: mixedIn treatment: yes           Yoga type: HathaMindfulness-based: yesInterventionist(s): not reportedDuration & frequency: 3 mo, weeklySession length: 90 min                                                                        Comparison group: waitlistFollow-up: 3 moOutcomes: fatigue, QoL
  Pruthis et al. (2012) ([@pkz098-B48])Country: USA            n = 30Age: 56.5 yType: breastStage: mixedIn treatment: yes            Yoga type: HathaMindfulness-based: noInterventionist(s): yoga instructorDuration & frequency: 3 mo, \<1×/wkSession length: 60 min                                                                     Comparison group: waitlistFollow-up: 3 moOutcomes: fatigue, QoL, depression
  Rahmani et al. (2015) ([@pkz098-B49])Country: Iran           n = 24Age: 43.7 yType: breastStage: mixedIn treatment: not reported   Yoga type: "group-conscious" yogaMindfulness-based: yesInterventionist(s): psychologistDuration & frequency: 2 mo, weeklySession length: 120 min                                                      Comparison group: usual careFollow-up: 2 moOutcomes: fatigue, QoL
  Sohl et al. (2016) ([@pkz098-B50])Country: USA               n = 15Age: 61.0 yType: colorectalStage: mixedIn treatment: yes        Yoga type: not reportedMindfulness-based: yesInterventionist(s): yoga instructorDuration & frequency: 2 mo, \>1×/wkSession length: 15 min                                                             Comparison group: empathic attention/listeningFollow-up: 2 moOutcomes: fatigue, QoL
  Sprod et al. (2015) ([@pkz098-B51])Country: USA              n = 97Age: 66.4 yType: breastStage: mixedIn treatment: no             Yoga type: HathaMindfulness-based: yesInterventionist(s): yoga instructorDuration & frequency: 1 month, \>1×/wkSession length: 75 min                                                                 Comparison group: usual careFollow-up: 1 monthOutcomes: fatigue
  Stan et al. (2016) ([@pkz098-B52])Country: USA               n = 34Age: 62.1 yType: breastStage: earlyIn treatment: no             Yoga type: HathaMindfulness-based: yesInterventionist(s): yoga instructorDuration & frequency: 3 mo, \>1×/wkSession length: 90 min                                                                    Comparison group: strengthening exercisesFollow-up: 3 moOutcomes: fatigue, QoL
  Taso et al. (2014) ([@pkz098-B53])Country: Taiwan            n = 60Age: 49.3 yType: breastStage: mixedIn treatment: yes            Yoga type: AnusaraMindfulness-based: yesInterventionist(s): yoga instructorDuration & frequency: 2 mo, \>1×/wkSession length: 60 min                                                                  Comparison group: usual careFollow-up: 2 moOutcomes: fatigue
  Taylor et al. (2018) ([@pkz098-B32])Country: USA             n = 26Age: 53.8 yType: breastStage: mixedIn treatment: no             Yoga type: restorativeMindfulness-based: yesInterventionist(s): yoga instructorDuration & frequency: 2 mo, weeklySession length: 75 min                                                               Comparison group: usual careFollow-up: 2 moOutcomes: fatigue, depression
  Vadiraja et al. (2009) ([@pkz098-B54])Country: India         n = 88Age: not reportedType: breastStage: mixedIn treatment: yes      Yoga type: PranayamaMindfulness-based: yesInterventionist(s): yoga instructorDuration & frequency: 1.5 mo, \>1×/wkSession length: 60 min                                                              Comparison group: health educationFollow-up: 1.5 moOutcomes: fatigue
  Vadiraja et al. (2017) ([@pkz098-B55])Country: India         n = 64Age: 50.5 yType: breastStage: lateIn treatment: not reported    Yoga type: PranayamaMindfulness-based: yesInterventionist(s): yoga instructorDuration & frequency: 3 mo, not reportedSession length: not reported                                                     Comparison group: health educationFollow-up: 3 moOutcomes: fatigue
  Vardar-Yagli et al. (2015) ([@pkz098-B56])Country: Turkey    n = 40Age: 48.6 yType: breastStage: earlyIn treatment: no             Yoga type: PranayamaMindfulness-based: yesInterventionist(s): physiotherapistDuration & frequency: 1.5 mo, \>1×/wkSession length: 60 min                                                              Comparison group: exercise classFollow-up: 1.5 moOutcomes: fatigue, QoL
  Vardar-Yagli et al. (2015) ([@pkz098-B57])Country: Turkey    n = 20Age: 68.7 yType: breastStage: earlyIn treatment: no             Yoga type: PranayamaMindfulness-based: yesInterventionist(s): physiotherapistDuration & frequency: 2 mo, weeklySession length: 60 min                                                                 Comparison group: exercise classFollow-up: 2 moOutcomes: fatigue, QoL, depression

QoL = quality of life.

Synthesis of Results
--------------------

The outcome measures and calculated effect sizes with 95% confidence intervals for each study are listed in [Table 2](#pkz098-T2){ref-type="table"}. Yoga practice was associated with a small but statistically significant decrease in fatigue from preintervention to the first follow-up when compared with a control group (n = 29, g* *=* *0.45, 95% confidence interval \[CI\] = 0.09 to 0.82, *P* = .013; [Figure 2](#pkz098-F2){ref-type="fig"}). When active control groups (ie, exercise, stretching) were separated from waitlist control groups and usual care, control group type was a statistically significant moderator of both fatigue and depression outcomes, with yoga interventions performing better in both areas when compared with waitlist control and usual care but not when compared with active control (n = 29, Q\[4\] = 7.14, *P* = .0363). Statistically significant heterogeneity was present in this model (I^2^ = 90.87%, Q\[28\] = 306.71, *P* ≤ .0001), indicating a significant amount of between-studies variability in study outcomes. This heterogeneity suggests that our random-effects model is appropriate and that moderator analyses may help clarify generalizability of results.

![Forest plot for fatigue effect sizes. RE = Random Effects.](pkz098f2){#pkz098-F2}

###### 

A summary of the outcomes and effect sizes for yoga intervention trials[\*](#tblfn2){ref-type="table-fn"}

  Study (year)                                                      Follow-up, mo                Fatigue             QoL          Depression
  ---------------------------------------------------------- --------------------------- ----------------------- ------------ ------------------
  Banasik et al. (2009) ([@pkz098-B16])                                   2                  FACT-B Fatigue       FACT-B QoL         ---
  1.67 (0.60 to 2.75)                                            5.59 (4.66 to 6.52)                                          
  Ben-Josef et al. (2017) ([@pkz098-B33])                                 2                        BFI               ---             ---
  4.96 (3.84 to 6.08)                                                                                                         
  Bower et al. (2012) ([@pkz098-B34])                                     3                        FSI               ---            BDI-II
  −0.92 (−1.66 to −0.18)                                         0.73 (0.00 to 1.46)                                          
  Carson et al. (2009) ([@pkz098-B35])                                    2                Daily fatigue diary       ---       Daily mood diary
  0.75 (−0.05 to 1.55)                                          0.35 (−0.22 to 0.92)                                          
  Chakrabarty et al. (2015) ([@pkz098-B36])                              1.5                      CFS-F              ---             ---
  4.20 (2.77 to 5.63)                                                                                                         
  Chandwani et al. (2014) ([@pkz098-B37])                                1.5                       BFI              SF-36           CES-D
  −0.67 (−1.05 to −0.28)                                      −17.18 (−17.70 to −16.67)    3.45 (2.85 to 4.04)                
  Chaoul et al. (2018) ([@pkz098-B38])                                    1                        BFI               ---             ---
  0.13 (0.07 to 1.46)                                                                                                         
  Cramer et al. (2015) ([@pkz098-B39])                                    3                      FACIT-F          FACT-B QoL        HADS-D
  0.61 (−0.20 to 0.46)                                           5.85 (5.21 to 6.48)      0.37 (−0.26 to 0.99)                
  Cramer et al. (2016) ([@pkz098-B40])                                   2.5                     FACIT-F          FACT-C QoL        HADS-D
  0.68 (0.25 to 1.12)                                            0.74 (0.20 to 1.28)      0.39 (−0.15 to 0.93)                
  Danhauer et al. (2009) ([@pkz098-B41])                                 2.5                     FACT-B             FACT-B          CES-D
  0.75 (0.14 to 1.36)                                            7.71 (7.10 to 8.32)       0.73 (0.12 to 1.34)                
  Dhruva et al. (2012) ([@pkz098-B42])                                   1.5                       PFS              SF-12           HADS-D
  0.02 (−1.00 to 0.96)                                           0.43 (−0.56 to1.42)      −0.01 (−0.99 to 0.97)               
  Johns et al. (2015) ([@pkz098-B43])                                   1.75                       FSI               ---            PSQ-8
  −0.95 (−1.99 to 0.08)                                        −1.30 (−1.82 to −0.79)                                         
  Jong et al. (2018) ([@pkz098-B44])                                      3                        MFI               ---            HADS-D
  0.38 (−0.06 to 0.82)                                           0.65 (0.21 to 1.10)                                          
  Kiecolt-Glaser et al. (2014) ([@pkz098-B17])                            3                      MFSI-SF             ---            CES-D
  0.17 (−0.26 to 0.60)                                          0.11 (−0.16 to 0.39)                                          
  Littman et al. (2012) ([@pkz098-B45])                                   6                      FACIT-F          FACT-G QoL         ---
  −0.27 (−0.23 to 0.76)                                          4.18 (3.68 to 4.68)                                          
  Lötzke et al. (2016) ([@pkz098-B46])                                    3                       CFS-D           EORTC GHS          ---
  −0.01 (−0.42 to 0.39)                                         −0.33 (=0.74 to 0.07)                                         
  Loudon et al. (2014) ([@pkz098-B47])                                    2                     10 CM VAS           LYMQOL           ---
  0.44 (−0.31 to 1.19)                                           2.99 (2.25 to 3.73)                                          
  Moadel et al. (2007) ([@pkz098-B18])                                    3                      FACIT-F          FACT-G QoL         ---
  −0.01 (−0.38 to0.35)                                         −0.41 (−0.77 to −0.04)                                         
  Pruthis et al. (2012) ([@pkz098-B48])                                   3                        BFI              FACT-G         POMS-Dep
  0.14 (−0.57 to 0.86)                                           1.07 (0.35 to 1.79)      0.00 (−0.71 to 0.71)                
  Rahmani et al. (2015) ([@pkz098-B49])                                   2                     EORTC C30         EORTC GHS          ---
  0.05 (−0.48 to 0.59)                                           7.87 (6.97 to 8.78)                                          
  Sohl et al. (2016) ([@pkz098-B50])                                      2                      FACT-C           FACT-C QoL         ---
  1.50 (0.35 to 2.64)                                            4.38 (3.26 to 5.50)                                          
  Sprod et al. (2015) ([@pkz098-B51])                                     1                      MFSI-SF             ---             ---
  −2.12 (−2.62 to−1.62)                                                                                                       
  Stan et al. (2016) ([@pkz098-B52])                                      3                      MFSI-SF          FACT-B QoL         ---
  −0.19 (−0.87 to 0.48)                                        −1.62 (−2.29 to −0.95)                                         
  Taso et al. (2014) ([@pkz098-B53])                                      2                  BFI (Taiwanese)         ---             ---
  1.56 (0.99 to2.14)                                                                                                          
  Taylor et al. (2018) ([@pkz098-B32])                                    2                        BFI               ---            CES-D
  0.53 (−0.26 to 1.31)                                           0.81 (0.00 to 1.61)                                          
  Vadiraja et al. (2009) ([@pkz098-B54])                                 1.5                       FSI               ---             ---
  0.66 (0.23 to 1.09)                                                                                                         
  Vadiraja et al. (2017) ([@pkz098-B55])                                  3                        FSI               ---             ---
  1.30 (0.76 to 1.84)                                                                                                         
  Vardar-Yagli et al. (2015) ([@pkz098-B56])([@pkz098-B1])               1.5                    EORTC C30         EORTC GHS          ---
  0.41 (−0.21 to 1.04)                                           4.05 (3.43 to 4.67)                                          
  Vardar-Yagli et al. (2015) ([@pkz098-B57])                              2                     10 CM VAS         NOTTINGHAM         BDI
  1.41 (0.43 to 2.39)                                          −5.66 (−6.57 to −4.75)      1.05 (0.12 to 1.99)                

BDI = Beck Depression Inventory; BFI = Brief Fatigue Inventory; CES-D = Center for Epidemiologic Studies Depression Scale; CFS = Chalder Fatigue Scale; CM VAS= centimeter Visual Analogue Scale; EORTC = European Organisation for Research and Treatment of Cancer; FACIT-F = Functional Assessment of Chronic Illness Therapy-Fatigue Scale; FACT-B = Functional Assessment of Cancer Therapy-Breast Cancer; FSI = Fatigue Symptom Inventory; GHS = Global Health Score; HADS-D = Hospital Anxiety and Depression Scale-Depression Subscale; LYMQOL = Lymphoedema Quality of Life Scale; MFSI = Multidimensional Fatigue Symptom Inventory; PFS = Piper Fatigue Scale; POMS-Dep = Profile of Mood States-Depression Subscale; PSQ-8 = Personal Health Questionnaire Depression Scale; QoL = quality of life; SF = Short Form Health Survey.

Yoga type (coded physical poses vs nonphysical poses) was a statistically significant moderator of the relationship between yoga practice and fatigue; nonphysical yoga types, such as pranayama interventions, were still effective but less effective than physical yoga types (n = 29, Q\[1\] = 11.66, *P* = .022, I^2^ = 94.41%). Neither timing of treatment (during vs posttreatment) nor patient clinical characteristics were found to be statistically significant moderators of the effects of yoga practice on outcomes (n = 29, cancer type: *P* = .27, I^2^ = 99.79%; cancer stage dichotomized as late vs early: *P* = .78, I^2^ = 99.99%), although it is important to note that this may be due to a lack of power to detect moderation.

Yoga practice was associated with a moderate decrease in depression (n = 12, g* *=* *0.72, 95% CI = 0.20 to 1.24, *P* = .007, I^2^ = 89.82%; [Figure 3](#pkz098-F3){ref-type="fig"}) but was not associated with statistically significant changes in quality of life (n = 17, *P* = .48, I^2^ = 99.75%; [Figure 4](#pkz098-F4){ref-type="fig"}). Statistically significant heterogeneity was present in both models (depression: Q\[11\] = 108.09; quality of life: Q\[16\] = 6361.84, both *P* \< .0001). Session length was a statistically significant moderator of the relationship between yoga practice and depression with longer sessions associated with stronger effects (n = 12, Q\[10\] = 4.5182, *P* = .033, I^2^ = 84.08%).

![Forest plot for depression effect sizes. RE = Random Effects.](pkz098f3){#pkz098-F3}

![Forest plot for quality of life effect sizes. RE = Random Effects.](pkz098f4){#pkz098-F4}

Risk of Bias Across Studies
---------------------------

Asymmetric funnel plots suggested evidence for publication bias for several analyses, including examination of the primary outcome of fatigue ([Figure 5](#pkz098-F5){ref-type="fig"}). Asymmetry of findings revealed a lack of published studies with smaller sample sizes and negative or nonsignificant findings. In addition, asymmetric funnel plots suggested the presence of outlier effect sizes, particularly for fatigue. Trim-and-fill analyses resulted in modified effect size estimates ([Table 3](#pkz098-T3){ref-type="table"}). However, notably, the statistical significance of all estimates remained unchanged. The direction of the quality-of-life analyses changed but remained nonsignificant, suggesting a large amount of variability present in published studies that may be largely influenced by outlier effect sizes.

![Publication bias funnel plot for fatigue outcomes.](pkz098f5){#pkz098-F5}

###### 

Comparison of primary effect sizes with trim and fill analyses

  Variable              Primary effect size                 Trim and fill effect size
  ------------ ------------------------------------- ---------------------------------------
  Fatigue       g = 0.45; I^2^ = 90.87%, *P* = .013    g = 0.43, I^2^ = 90.82%, *P* = .02
  Depression    g = 0.72; I^2^ = 89.92%, *P* = .007   g = 1.071, I^2^ = 93.29%, *P* \< .001
  QoL           g = 1.07, I^2^ = 99.75%, *P* = .48    g = −1.5671, I^2^ = 99.77%, *P* = .27

g = Hedges\' g effect size measure; I^2^ = percentage of variation across studies that is due to heterogeneity rather than chance; QoL = quality of life;

In addition, an examination of studies using intent-to-treat analyses was conducted as a more conservative estimate of yoga's effects on fatigue, depression, and quality of life. Notably, although reduced, both the direction and statistical significance of estimated effect sizes for fatigue (n = 15, g* *=* *0.24, 95% CI = 0.03 to 0.37, *P* = .044) and depression (n = 9, g* *=* *0.39, 95% CI = 0.17 to 0.62, *P* = .0006) did not change when only studies using an intent-to-treat approach were included (n = 15). Yoga practice was not associated with a statistically significant effect on increasing quality of life. (n = 11, g= 2.46, 95% CI = −0.06 to 4.93, *P* = .055).

Clinical significance as estimated by pretreatment and posttreatment means in the yoga practice group showed that a clinical level of depression (identified as a score ≥16 on the CES-D measure) pretreatment (mean = 16.74) was reduced to a nonclinical level at posttreatment (mean = 9.55). Changes in fatigue scores on multiple scales (BFI, FACIT, FSI), while statistically significant, were not clinically significant as defined by an average change greater than three points from pre- to posttreatment.

Discussion
==========

The purpose of this review was to examine effects of yoga randomized controlled trials on fatigue, depression, and quality of life in cancer survivors. Yoga-based interventions were shown to be generally effective when compared with waitlist, standard care, and active comparison conditions in the treatment of fatigue and depressive symptoms in cancer survivors. These effects were generally robust when publication bias and study quality were taken into account.

These results appear to roughly match the weighted mean effects in prior meta-analyses of the impact of yoga practice on depression in breast cancer survivors ([@pkz098-B20]) and in heterogeneous cancer groups ([@pkz098-B25]). The results of this review are in contrast to the findings of Lin et al. (2011), the most recent systematic review of yoga interventions in a heterogeneous group of cancer survivors; their findings suggest no statistically significant difference between yoga practice and comparison groups in the treatment of CRF. However, this may be due to the restricted number of studies measuring CRF included in their sample (N = 4).

Notably, depressive symptoms accounted for a large portion of the heterogeneity in the fatigue model (*R*^2^ = 36.32%). This is likely due to a persistent cluster of cancer-related symptoms that many patients continue to experience posttreatment, including both fatigue and mood disturbances as well as sleep problems and cognitive impairment ([@pkz098-B58]). A multifactorial model is likely to explain the shared variance between posttreatment symptoms, including potential underlying factors such as increased systemic inflammation, DNA damage, and disruption to endocrine and circadian rhythms ([@pkz098-B59]). In the context of yoga interventions, our results suggest that yoga practice acts in parallel on both depressive symptoms and fatigue, with shared variance between the two posttreatment symptoms contributing to difficulties in further exploring mechanisms underlying yoga's efficacy. Although a few studies have explored associations between yoga practice and inflammation ([@pkz098-B17],[@pkz098-B62]) or yoga practice and cortisol dysregulation ([@pkz098-B16]) in the context of cancer, at present there are not enough studies to systematically analyze these effects. Future studies should include biological variables that may allow for systematic exploration of potential underlying factors (ie, inflammatory cytokines such as interleukin-6, salivary cortisol, blood sampling for single-cell gel electrophoresis, or detailed sleep sampling such as an actigraphy watch).

Our secondary aim was to assess specific patient and intervention characteristics that may be potential moderators of intervention effects. Our moderation results suggest specific components of interventions that are likely related to larger decreases in fatigue and depressive symptoms. Yoga type was associated with differences in fatigue reductions; while nonphysical yoga practices such as pranayama (breathing techniques) were effective in reducing fatigue, other more physical yoga types were associated with larger reductions in fatigue. Due to large heterogeneity between yoga postures and foci during practice between yoga types as well as a lack of published study protocol for many studies included in this meta-analysis, it is difficult to assess other common components of yoga types associated with increased effectiveness. Notably, inclusion of mindfulness was not associated with any significant change in effect size estimates for fatigue or depressive symptoms, suggesting that mindfulness may not be the sole effective component of yoga interventions. The length of the yoga session was associated with differences in the reduction of depressive symptoms, with longer sessions associated with greater reductions in depressive symptoms. It is notable that yoga was significantly more effective compared with "passive" control groups (ie, usual care and waitlist control) but equivalent to "active" control groups (ie, exercise and stretching). This may indicate a broader mechanism at work that is not limited to yoga alone, such as the overall benefits of physical activity in potentially reducing inflammation ([@pkz098-B63]) or the possibility that yoga acts as a component of the larger mechanism of behavioral activation, where patients improve by increasing pleasant activities and positive interactions with their environment ([@pkz098-B64],[@pkz098-B65]).

This review has several limitations. At the conceptual level, this review is limited in scope because fatigue, quality of life, and depression were the only outcomes included. Although sleep problems and cognitive impairment may also be affected by yoga practice due to their presence in the posttreatment symptom cluster affecting many cancer patients, these three outcomes were selected because they were the most likely to be reported in the available literature and across the widest variety of cancer populations. Although there are too few studies at present to conduct a meta-analysis, findings from a recent study do suggest that yoga practice is associated with both decreases in sleep disruption and improvements in memory in cancer patients ([@pkz098-B66]).

In addition, construct validity is an important limitation to our findings due to the overlapping variance between fatigue and depressive symptoms as a result of those outcomes being part of a larger, overlapping cluster of posttreatment symptoms. Fatigue (ie, loss of energy) is often one potential diagnostic criterion for major depressive disorder, and all results should be interpreted with this limitation in mind. The search strategy included only articles published in English in peer-reviewed journals. It is likely that there are other studies published in other languages or not published due to null findings that may have contributed to knowledge of yoga interventions in cancer survivors. Additionally, asymmetry of findings revealed a lack of published studies with smaller sample sizes and negative or nonsignificant findings. This is particularly concerning considering the large number of pilot trials in this area of research and is strong evidence of publication bias. Asymmetric funnel plots suggested the presence of outlier effect sizes, particularly for fatigue. These large, positive effect sizes from studies with smaller sample sizes and greater standard error may be disproportionately influencing conclusions about the overall effects of yoga, and these conclusions should be made with caution. Efforts were made to obtain publications related to the studies included in this analysis, such as published study protocols and secondary analyses such as longitudinal follow-ups. However, most studies did not have additional resources available. It is important for future research in this area to incorporate both specific and standardized reporting methods that describe specific intervention components, particularly specific components of yoga poses. Additionally, despite efforts to include other cancer types, many available studies included primarily female breast cancer survivors from higher socioeconomic backgrounds; it is important for future research to be inclusive of the wide variety of cancer diagnoses and individuals present in the overall population of cancer survivors. Finally, the median sample size of these studies is small (N = 62), suggesting the need for larger randomized controlled trials in this area of research, particularly trials that include long-term follow-up to assess potential sustained effects of yoga interventions in this population.

Despite the limitations of this review, it is evident that yoga interventions demonstrate promise for effectively reducing fatigue and depressive symptoms in cancer patients. Although the current findings demonstrate the efficacy of yoga interventions in randomized controlled trials, these interventions have not yet been implemented into standard survivorship care. Future research should focus on both methods of promoting reductions in CRF and depressive symptoms and methods of making these interventions sustainable. Many of the interventions described in this review are not typically covered or reimbursed by health insurance. Dissemination of mind-body interventions with a focus on developing multidisciplinary teams within oncology as well as utilizing community resources are important next steps for this research.

In conclusion, our meta-analysis of published, randomized controlled trials showed that yoga interventions improved CRF and symptoms of depression in cancer survivors. Our moderation results suggest specific components of interventions that are related to larger decreases in these areas; specific yoga types are associated with greater decreases in CRF, and longer session length is associated with greater decreases in depressive symptoms. Given the large amount of variability both seen across these studies and present in the growing population of cancer survivors, much work is still needed to better understand what aspects of these interventions are most effective across different cancer diagnoses as well as what mechanisms may underlie similar reductions across symptoms in the same symptom cluster.
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